Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK120 in Moderate-to-Severe Atopic Dermatitis (Ib/II)
CTR20212033Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing AK120 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events, serious adverse events, and clinically significant findings (laboratory tests, 12-lead ECG, vital signs) during Ib phase, Pharmacokinetic parameters of AK120 during Ib phase and 2 more. Started Aug 2021; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20212033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212033.